Maria L. Amaya

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia

Shanshan Pei, Daniel A. Pollyea, Annika Gustafson et al. · Cancer Discovery · 2020 · 518 citations

Mixed-phenotype Acute Leukemia, Immunology, Pharmacotherapy +19

Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells

Courtney L. Jones, Brett M. Stevens, Daniel A. Pollyea et al. · Cell stem cell · 2020 · 216 citations · Full text

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +7

<i>Trypanosoma c</i><i>ruzi</i> Trans-sialidase Operates through a Covalent Sialyl−Enzyme Intermediate:  Tyrosine Is the Catalytic Nucleophile

Andrew G. Watts, Iben Damager, Maria L. Amaya et al. · Journal of the American Chemical Society · 2003 · 207 citations

Venetoclax for AML: changing the treatment paradigm

Daniel A. Pollyea, Maria L. Amaya, Paolo Strati et al. · Blood Advances · 2019 · 162 citations · Full text

Hematological Malignancy, Oncology, Venetoclax-based Therapies +14

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia

Evan Cherry, Diana Abbott, Maria L. Amaya et al. · Blood Advances · 2021 · 160 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +12